|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/497 | (2006.01) |
| A61K 31/497 | (2013.01) | ||
| A61K 31/5377 | (2006.01) | ||
| A61K 31/5377 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 37/00 | (2006.01) | ||
| A61P 37/00 | (2018.01) |
| (11) | Number of the document | 4069237 |
| (13) | Kind of document | T |
| (96) | European patent application number | 20829249.0 |
| Date of filing the European patent application | 2020-12-03 | |
| (97) | Date of publication of the European application | 2022-10-12 |
| (45) | Date of publication and mention of the grant of the patent | 2025-04-09 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2020/063176 |
| Date | 2020-12-03 |
| (87) | Number | WO 2021/113557 |
| Date | 2021-06-10 |
| (30) | Number | Date | Country code |
| 201962943720 P | 2019-12-04 | US | |
| 202063010524 P | 2020-04-15 | US |
| (72) |
SANDS, Arthur T. , US
KELLY, Aileen , US
|
| (73) |
Nurix Therapeutics, Inc. ,
1700 Owens Street Suite 205, San Francisco, CA 94158,
US
|
| (54) | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY |
| BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY |